HHS will not act against pharmacies compounding BPC-157, TB-500 and four other peptides, under ten conditions
The Department of Health and Human Services said on October 30, 2026 that it will not act against licensed pharmacies and physicians compounding six peptides, BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, if they meet ten conditions, while the FDA decides through rulemaking whether to list them.
HHS published a notice of availability of its "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (RIN 0910-ZD94)[1] in the Federal Register on October 30[1]. Comments were open for two weeks after publication[1]. The notice's background calls the document a draft[1]. The policy applies while the list of bulk substances that 503A pharmacies may compound with is developed through rulemaking[1]. It does not establish any rights and is not binding on HHS or the public[1], and HHS may revisit it if a safety signal or product quality issue arises[1].
The policy names six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500[2]. Emideltide, also called DSIP, which the FDA's advisory committee discussed in July[3], is not on it. HHS does not intend to act against a state-licensed pharmacy, federal facility or licensed physician compounding with one of the six when every condition is met[2], until a final rule decides whether that peptide goes on the list[2]. FDA rulemakings may later propose adding some or all of them[1].
HHS's stated reason is to discourage the widespread use of research-use-only peptides from foreign manufacturers that pose a safety risk to US patients[2]. The policy is about what pharmacies, federal facilities and physicians may compound[2]. Nothing in it makes a vial sold "for research" a compounded drug.
The conditions
The peptide must be on the list and match the identity in Appendix B. Among the rest:
- The bulk substance comes from a facility registered with FDA under section 510, with a valid certificate of analysis[2], and the original manufacturer, not a later repacker or distributor, is registered[2].
- Compounders report what they compound, serious adverse events and quality problems to FDA and to the states[2].
- The label says "This is a compounded drug product. Not for resale."[2]
- One active ingredient from the list per product[2].
- An oral form needs documentation that it is absorbed adequately in humans[2].
- The only device allowed is an FDA 510(k)-cleared syringe[2].
- Every product needs a patient-specific prescription[2].
Which forms
Each peptide is covered only in named forms. BPC-157: subcutaneous, intramuscular, oral and topical[2]. TB-500: subcutaneous or intramuscular injection[2]. Epitalon: injection, dispensed in intermittent courses[2]. Semax: intranasal only[2]. KPV: topical and oral[2]. MOTS-c: subcutaneous or intramuscular injection[2].
For every one of the six, the policy records that the FDA's drug center recommended against listing it and the advisory committee voted in favor[2].
References
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances — Federal Register
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B) — US Department of Health and Human Services, Office of the Secretary
- Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List — Federal Register
Comments
Sign in to join the conversation.
No comments yet.